Site-Specific Fluorescence Polarization for Studying the Disaggregation of α-Synuclein Fibrils by Small Molecules by Haney C.M. et al.
Site-Specific Fluorescence Polarization for Studying the
Disaggregation of α‑Synuclein Fibrils by Small Molecules
Conor M. Haney,† Christina L. Cleveland,† Rebecca F. Wissner,†,∥ Lily Owei,† Jaclyn Robustelli,†
Malcolm J. Daniels,‡ Merve Canyurt,†,⊥ Priscilla Rodriguez,† Harry Ischiropoulos,§ Tobias Baumgart,†
and E. James Petersson*,†
†Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104, United States
‡Pharmacology Graduate Group, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, Pennsylvania 19104, United
States
§Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, United States
*S Supporting Information
ABSTRACT: Fibrillar aggregates of the protein α-synuclein
(αS) are one of the hallmarks of Parkinson’s disease. Here, we
show that measuring the fluorescence polarization (FP) of
labels at several sites on αS allows one to monitor changes in
the local dynamics of the protein after binding to micelles or
vesicles, and during fibril formation. Most significantly, these
site-specific FP measurements provide insight into structural
remodeling of αS fibrils by small molecules and have the
potential for use in moderate-throughput screens to identify
small molecules that could be used to treat Parkinson’s disease.
Misfolding of the intrinsically disordered neuronal proteinα-synuclein (αS) has been implicated in the patho-
genesis of several debilitating neurodegenerative disorders,
including Parkinson’s disease (PD).1 Although it is generally
accepted that αS exists as a disordered monomer in vivo, some
controversial studies have suggested that the physiologically
relevant form of αS is actually a metastable tetramer.2−6
Regardless of its initial state, the protein exhibits remarkable
structural plasticity.7 Upon binding to membrane lipids, αS
monomers adopt α-helical conformations.8,9 Misfolding of
monomeric αS leads to aberrant oligomerization and ultimately
fibrillization. The insoluble cross-β strand fibrils that are the
hallmarks of PD can be formed from oligomers or direct
addition of monomer units.10−16 Two exciting recent studies of
fibril structure, electron diffraction of αS fragments and solid
state nuclear magnetic resonance (NMR) of the full length
protein, have provided insight into the fold of fibrillar αS, but
the molecular mechanisms of αS misfolding have yet to be
described.17,18 Common amyloid binding dyes, such as
thioflavin T (ThT) and Congo Red (CR), can be used to
detect the presence of αS fibrils.19 Although extrinsic dyes are
routinely employed to monitor the kinetics of amyloid
formation, the structural information obtained from these
experiments is limited.
It has recently been shown that preformed fibrils can recruit
endogenous intracellular αS and convert it into a pathogenic
form in vivo.20 Accordingly, small molecules that can remodel
and/or disaggregate αS fibrils into less toxic species are being
investigated as potential therapeutics to combat the progression
of PD.21−27 Although amyloid binding dyes such as ThT and
CR are used in high-throughput screening to identify modifiers
of aggregation, these dyes cannot be used to reliably detect
morphological changes of αS induced by small molecules, as it
is likely that the dyes and candidate compounds compete for
similar binding sites.28,29 Moreover, the optical properties of
amyloid binding dyes may be affected by the presence of other
compounds in solution. Indeed, our own analysis of small
molecule remodeling experiments using ThT shows that the
change in ThT fluorescence does not accurately reflect the
change in the amount of insoluble αS aggregates following
small molecule treatment (see Figures S17, S25, and S26 and
discussion below). Improved methods for monitoring the
aggregation and disaggregation of αS that yield meaningful
structural information and are not susceptible to these
drawbacks would greatly facilitate our understanding of these
crucial processes.
Fluorescence polarization (FP) spectroscopy is a powerful
technique for monitoring changes in the conformational
mobility of fluorescently labeled molecules.30 By incorporating
a fluorescent label into a protein, one can use FP to obtain a
range of dynamic information. In 2007, the Lee laboratory
demonstrated that FP can be used to monitor the aggregation
of αS.31 In this study, the authors prepared nonspecifically
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labeled αS by treating the recombinant protein with an amine-
reactive dye. Over the course of aggregation, FP values of the
labeled protein increased in a manner that was consistent with a
nucleation-dependent process characteristic of αS assembly.32
Notably, the observed increase in polarization preceded fibril
detection by amyloid binding dyes, suggesting that FP can be
used to detect the formation of early oligomeric intermediates.
Although this initial report demonstrated the utility of FP for
monitoring αS aggregation, the proteins used in these studies
consisted of heterogeneous mixtures of labeled constructs.
Therefore, we sought to determine whether site-specifically
labeled αS could be used in conjunction with FP to distinguish
local changes in conformational freedom that occur during
misfolding and aggregation of αS. Although several small
molecules have been reported to remodel and/or disaggregate
preformed αS fibrils, robust, moderate- to high-throughput
methods for examining this process in real time are currently
lacking. Here, we show that we can use FP to monitor the
conformational changes within αS fibrils induced by small
polyphenolic compounds and demonstrate that site-specific
labels yield insight into their interaction with αS fibrils and
subsequent local conformational changes (Table 1).
■ EXPERIMENTAL PROCEDURES
Fluorescence Polarization (FP) Measurements. The
concentrations of high-performance liquid chromatography
(HPLC)-purified fluorescein maleimide (Fam)-labeled proteins
were determined by UV−vis absorbance using a molar
extinction coefficient of 68000 M−1 cm−1 at 494 nm. The
concentration of wild-type (WT) αS was also determined using
UV−vis absorbance using a molar extinction coefficient of 5120
M−1 cm−1 at 280 nm. Prior to FP measurements, the Fam-
labeled mutants were diluted into a solution of WT αS in a 1:99
molar ratio to achieve a final total protein concentration of 100
μM; 100 μL portions of 10 μM samples were prepared in
triplicate by diluting the 100 μM stock into αS buffer [20 mM
Tris and 100 mM NaCl (pH 7.5)]. Each sample was then
gently vortexed and pipetted into an untreated Corning Costar
black, clear flat bottom nonsterile 96-well plate (part no. 07-
200-567). All FP measurements here and below were taken
using a Tecan (Mannedorf, Switzerland) Infinite F200 Pro
microplate reader equipped with excitation (485 ± 20 nm) and
emission (535 ± 25 nm) filters for Fam fluorescence.
Fluorescence Polarization Measurements in Sodium
Dodecyl Sulfate (SDS). To measure the FP values of each
mutant in the presence of SDS, three 20 μL replicates were
prepared by dilution of αS−CFamX protein stock solutions
(concentration determined as described above) with a 25 mM
SDS stock in αS buffer and αS buffer to yield samples
comprised of 1 μM αS−CFamX in 10 mM SDS, 20 mM Tris, and
100 mM NaCl (pH 7.5). The samples were gently vortexed and
pipetted into an untreated Grenier black, clear flat bottom
nonsterile 384-well plate (part no. 781209) and assessed on the
Tecan F200 Pro microplate reader after incubation at room
temperature for 5 min.
FP Measurements in Large Unilamellar Vesicles
(LUVs). LUVs were prepared using 100% 1,2-dioleoyl-sn-
glycero-3-phospho-L-serine (DOPS). Lipids were vacuum-dried
to form a lipid film and rehydrated with 150 mM NaCl, 20 mM
HEPES, and 1 mM TCEP (pH 7.4). Liposome solutions were
sonicated for 20 min and extruded through 200 nm Whatman
nuclepore membranes (GE Life Sciences, Pittsburtgh, PA) 15
times. Liposome solutions were stored at 4 °C. To measure the
FP values of each mutant in the presence of DOPS LUVs, three
20 μL replicates were prepared in bulk at 300 nM αS−CFamX
and 1.5 mM 200 nm DOPS LUVs (concentration of total
DOPS) in 20 mM HEPES, 150 mM NaCl, pH 7.0 buffer
(vesicle buffer). The samples were gently vortexed and pipetted
into an untreated Grenier black, clear flat bottom nonsterile
384-well plate and assessed on the Tecan F200 Pro microplate
reader after incubation at room temperature for 5 min.
Fluorescence Microscopy Imaging of αS−CFamX Bound
to Giant Unilamellar Vesicles (GUVs). GUVs composed of
99.7% DOPS and 0.3% Texas red-1,2-dihexadecanoyl-sn-
glycero-3-phosphoethanolamine triethylammonium salt
(Texas Red-DHPE) were prepared by electroformation in a
300 mM sucrose solution as previously described.33 An imaging
chamber was formed between two coverslips (25 mm × 25
mm). The chamber had a total volume of 36 μL and was filled
by dilution of a 6 μM GUV dispersion into buffer, yielding a
solution with final concentrations of 200 mM sucrose, 33 mM
NaCl, 7 mM HEPES, 0.3 mM TCEP, and ∼0.3−0.5 μM total
αS−CFamX (pH 7). The protein- and GUV-containing solution
was incubated for at least 10 min before being imaged with a
confocal fluorescence microscope using a 60×, 1.1 NA objective
lens (Olympus, Center Valley, PA). The incubation and
imaging processes were performed at room temperature (20
°C).
Aggregation Assays. Aggregation reactions were per-
formed by diluting each labeled construct into a mixture of WT
αS in a 1:99 molar ratio to a final concentration of 100 μM.
Aggregation samples were prepared in triplicate. Aggregation
was initiated by shaking the solution at 37 °C and 1500 rpm on
an IKA MS3 digital orbital shaker in parafilm-sealed 1.7 mL
Eppendorf tubes to ensure minimal solvent evaporation. At
each time point, aliquots were removed from the aggregation
reaction mixture and assessed by FP and CR absorbance in
separate assays. Fluorescence polarization measurements were
obtained by dilution of 10 μL of the aggregation solution into
90 μL of αS buffer (100 μL total volume). The samples were
gently vortexed and transferred to an untreated Corning Costar
black, clear flat bottom nonsterile 96-well plate and analyzed on
a Tecan F200 plate reader. CR absorbance measurements were
taken by dilution of 10 μL of the aggregation solution into 140
μL of 20 μM CR dissolved in αS buffer. The samples were
allowed to sit at room temperature for 15 min prior to being
transferred to an untreated Corning Costar black, clear flat
bottom nonsterile 96-well plate and absorbance measurements
acquired on a Tecan M1000 plate reader using a wavelength
range of 230−700 nm. Following completion of the aggregation
assay, the samples were split into two separate aliquots; fibrils
in each aliquot were then pelleted by centrifugation (13200
rpm for 90 min at 4 °C), and the supernatant was removed.
One aliquot was immediately resuspended in an equal volume
(relative to supernatant) of αS buffer, and the measurements
described above were repeated on the resuspended fibril
sample. The second aliquot was frozen at −20 °C until it was
analyzed by transmission electron microscopy (TEM) as
described below.
Small Molecule Remodeling Assays. The 1% Fam-
labeled αS fibrils of each labeled mutant were prepared for
small molecule remodeling assays as described above. Stock
solutions of dopamine, epigallocatechin gallate (EGCG), and
nordihydroguiaretic acid (NDGA) were prepared by mass-to-
volume ratio at 1 mM in αS buffer; NDGA was solubilized in
20% EtOH. Small molecule stock solutions at 500 μM
Biochemistry Article
DOI: 10.1021/acs.biochem.6b01060
Biochemistry 2017, 56, 683−691
684
dopamine, 500 μM EGCG, and 500 μM NDGA were prepared
by 2-fold dilution of the 1 mM stocks in αS buffer; all stocks
were prepared immediately prior to the performance of each
remodeling assay. The final concentration of ethanol in the
NDGA-treated fibrils was 2% by volume. The remodeling assay
was first tested in triplicate by treating 10 μM αS fibrils with
100 μM freshly prepared dopamine, EGCG, and NDGA; as a
control, buffer was added to the fibrils in lieu of small
molecules. Controls were prepared by diluting 30 μL of the
resuspended 1% αS−CFamX fibrils in 270 μL of αS buffer, gently
vortexing, and splitting the sample into three wells, 100 μL per
well, of an untreated Corning Costar black, clear flat bottom
nonsterile 96-well plate. The fibril solutions to be treated with
the small molecules were prepared by diluting 90 μL of the
resuspended fibrils in 630 μL of αS buffer, gently vortexing, and
splitting the sample into nine wells, 80 μL per well of the same
plate as described above. Prior to the addition of the small
molecule solution to the αS fibrils, the FP for all the wells was
measured and the gain optimized. Small molecules were added
from freshly prepared 500 μM small molecule stock solutions in
αS buffer (20 μL/well, in triplicate) to start the assay. Over the
course of 3 h, the instrument performed the following actions
every 1.5 min: orbital shaking for 2 s with an amplitude of 1
mm followed by an FP measurement of all wells using the gain
optimized prior to the small molecule addition. All measure-
ments were taken at room temperature.
FP of Soluble and Insoluble Fractions after the Small
Molecule Remodeling Assay. At the end of the remodeling
assay (i.e., 3 h post-small molecule addition), the three
replicates from each condition (control, dopamine, EGCG,
and NDGA) were removed from the 96-well plate, combined,
and gently vortexed. After being vortexed, the combined
samples were split into four Eppendorf tubes at 60 μL per tube.
All of the samples were then pelleted by centrifugation (13200
rpm for 90 min at 4 °C) to separate the soluble and insoluble
fractions. Because it is difficult to completely remove all of the
supernatant without disturbing the pellet for small samples, the
following procedure was used. After centrifugation, the
following volumes of supernatant (soluble fraction) were
removed from each of the four tubes: 0, 10, 20, and 30 μL.
The 10, 20, and 30 μL portions of the supernatant that were
removed were combined, gently vortexed, and transferred to an
untreated Grenier black, clear flat bottom nonsterile 384-well
plate to be measured as the soluble fraction for the respective
positions and conditions. The removed supernatant was
replaced with the same volume of buffer containing the
respective small molecules. The small molecule solutions used
to replace the supernatant were prepared from the small
molecule stocks made at the start of the remodeling assay,
diluted to the same concentration as that used in the assay, and
centrifuged (13200 rpm for 10 min at 4 °C). All four pellets per
condition (the −0, −10, −20, and −30 μL soluble fraction
pellets) were then resuspended by vortexing at high speed. The
resuspended pellets were then transferred to an untreated
Grenier black, clear flat bottom nonsterile 384-well plate (split
into three wells per Eppendorf tube, 20 μL per well) to be
measured as the insoluble fractions. The FP measurememts of
these samples were used to extrapolate a FP measurement for
the corresponding insoluble material as described in the
Supporting Information.
Transmission Electron Microscopy (TEM). TEM was
performed on an FEI Tecnai T12 instrument with an
accelerating voltage of 120 kV. Fibril samples obtained from
aggregation and centrifugation and stored at −20 °C as dry
pellets were resuspended in 20 mM Tris and 100 mM NaCl
(pH 7.5). Glow-discharged carbon Formvar-coated 300-mesh
Cu grids were inverted over a 10 μL drop of sample and
allowed to rest for 2 min at room temperature. After this time,
the excess solution was wicked off and the grid was washed for
2 × 10 s with water, and the grids were stained for 3 × 15 s with
2% (w/v) ammonium molybdate (pH 7.8) in water. The grids
dried at room temperature for 2 min and then were imaged.
Images were collected at magnifications ranging from 11000×
to 42000×. TEM image analysis was performed manually using
Gatan Digital Micrograph software (Gatan, Inc., Pleasanton,
CA). Fibril length and width analysis is described in the
Supporting Information.
Small Molecule Remodeling TEM. Fibril samples
comprised of αS WT, 1% αS−CFam9 in 99% αS WT, or 1%
αS−CFam114 in 99% αS WT (10 μM fibril based on the
monomeric total αS concentration) were treated with
dopamine, EGCG, or NDGA (100 μM) in triplicate as
described above. Three hours after small molecule treatment
under plate reader-based kinetic assay conditions described
above, a representative single sample was removed from the
plate and used to prepare carbon Formvar-coated 300-mesh Cu
grids for negative-stain TEM as described above. Additional
images of these samples are shown in the Supporting
Information.
■ RESULTS AND DISCUSSION
Recently, we reported the use of inteins as purification tags for
the efficient production of labeled αS to study conformational
changes using Förster resonant energy transfer (FRET) and
cellular trafficking of fibrils.34 To produce a library of site-
specifically labeled αS for FP studies, we expressed constructs
as His6-tagged Mxe GyrA intein fusions containing single Cys
mutations (Figure 1). Following isolation of the intein-tagged
proteins from the cell lysate by Ni-NTA chromatography, each
construct was labeled using an excess of fluorescein maleimide
(Fam) for 3−5 h at 37 °C. After labeling, each construct was
further purified by ion-exchange chromatography and HPLC.
HPLC-purified proteins were characterized by matrix-assisted
laser desorption ionization mass spectrometry (MALDI-MS)
and polyacrylamide gel electrophoresis (PAGE) analysis.
MALDI-MS of trypsin digestion fragments confirmed that the
labeling of αS proceeded in a specific and quantitative manner
(see Figures S4−S7).
We began our studies by measuring the polarization values
associated with each labeled protein in detergent-free buffer. To
avoid intermolecular fluorophore interactions (such as homo-
FRET, which may lead to a decrease in polarization35), labeled
αS was diluted into a solution of WT αS in a 1:99 molar ratio
for most FP measurements [micelle and vesicle binding
experiments used 100% labeled αS (see the Supporting
Information for details)]. Because αS is intrinsically disordered,
we expected that FP values corresponding to monomeric αS
would be similar for each labeled mutant. Intriguingly, we
found that the polarization of the Fam label was dependent on
its location within the αS sequence. These results are consistent
with both in vitro and in cell NMR studies, suggesting that the
residues in the C-terminal tail (96−140) exhibit a degree of
conformational freedom greater than that of the residues
residing in the N-terminus (1−60) and the so-called non-
amyloid-containing (NAC, 61−95) domain.6,36
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To further demonstrate that site-specific labels yield
information about local αS dynamics, we took FP measure-
ments of each αS mutant bound to sodium dodecyl sulfate
(SDS) micelles or large unilamellar vesicles (LUVs). Previous
NMR and single-molecule fluorescence studies have shown that
upon binding to SDS, the first 98 residues of αS fold into a pair
of curved antiparallel helices that are connected by a short turn
region spanning residues 38−44.37,38 The helix−turn−helix
motif is followed by a predominantly disordered C-terminal tail
consisting of residues 98−140.37 However, in the presence of
LUVs, residues 1−98 of αS have been shown to adopt an
extended helical conformation by smFRET.39 In the presence
of SDS and 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS)
LUVs, constructs with Fam labels at position 9, 24, 42, 62, or
87 show increased FP, while constructs with Fam labels at
position 114, 123, or 136 show decreased FP (Figure 2 and
Figures S9 and S10). The increase in FP observed in the
presence of SDS versus DOPS LUVs for labels at position 42,
62, or 87 is consistent with a rearrangement from the micelle-
bound to vesicle-bound helical structures. Circular dichroism
(CD) spectroscopy measurements confirm that each labeled
construct adopts an α-helical conformation in the presence of
SDS (Figure S8a,b). We also wished to image the bound αS
constructs, because some evidence exists for remodeling of
liposomes by αS to form cylindrical micelles.40 While SDS
micelles and LUVs are too small for imaging, microscopy
images of DOPS giant unilamellar vesicles (GUVs) confirm
that our labeled αS constructs bind to the surfaces of vesicles.
Our FP data are consistent with the existing NMR and
electron paramagnetic resonance (EPR) structures of αS bound
to SDS micelles and previous studies of the αS conformation
bound to LUVs.9,37,39,41 They are also consistent with the
previous observation that monomeric, disordered αS has long-
range contacts between the N- and C-termini that are released
upon binding to micelles or vesicles42,43 (decreasing FP values
for C-terminal positions compared to monomer in buffer).
Importantly, these experiments show that despite αS being
bound to large, slowly rotating micelles or LUVs, the FP
measurements reflect the local dynamics of the protein around
the site of attachment of the dye to αS.
Next, we used FP to monitor the assembly of αS into
amyloid fibrils. Aggregation reactions were performed by
diluting each labeled construct into a mixture of WT αS in a
1:99 molar ratio and agitating the solution at 1500 rpm and 37
°C. Periodically, separate aliquots of the aggregation reaction
mixture were removed for FP and CR analysis. CR binding
assays demonstrated that the kinetic profiles of aggregation
assays containing 1% labeled αS are very similar to those
obtained using WT alone. Example data for αS−CFam9 are
shown in Figure 3; data for all other constructs are included in
the Supporting Information (Figure S12; Tables S3 and S4
detail forward aggregation kinetics for each construct).
Both FP and CR measurements generated sigmoidal curves
consistent with a nucleation-dependent mechanism of amyloid
aggregation. However, the kinetic profiles obtained using FP
varied on the basis of the position of the incorporated label.
The t1/2 for the changes in FP varied from 6.7 to 27 h. This
observation is consistent with some labeling positions leading
to retarded co-incorporation of the labeled protein with the
wild type (WT); several other explanations are plausible. For
example, it is also possible that these positions indicate
differences in local conformational restriction around the
labeled site in a time-dependent manner during aggregation,
or that addition of labeled protein perturbs the aggregation
pathway. While we interpret the change in t1/2 by FP relative to
CR as being indicative of slower co-incorporation of labeled
protein, further investigation of the mechanism of aggregation
as reported by FP is underway. Regardless, aggregation end
point assays showed that even constructs exhibiting a slower
increase in FP, such as αS−CFam42, were ultimately incorpo-
rated well into the fibrils. We determined the percent of
incorporation of labeled αS by gel imaging and the morphology
of the fibrils by TEM imaging (Figures S14, S15, S29, and S30;
these include larger versions of the TEM images shown in
Figure 3). These kinetic and end point assays show that our
chosen labeling positions were not highly disruptive to
Figure 1. Labeling α-synuclein (αS) for studies of aggregation. Protein
sequence of αS (top). Green circles indicate positions for fluorophore
attachment. Cys mutants of αS are purified using a C-terminal intein
tag (bottom left), treated with β-mercaptoethanol (β-ME) to cleave
the intein, and labeled with fluorescein maleimide (Fam). Monomers
of αS can form helices when bound to membranes (bottom right).
Disordered monomers can misfold and aggregate to form oligomers or
fibrils. Aggregation experiments were performed with 1% labeled
protein to prevent fluorophore−fluorophore interactions.
Figure 2. In the left panel, fluorescence polarization (FP) reveals local
dynamics in proteins bound to micelles or vesicles. FP measurements
of αS constructs labeled with Fam at the noted positions, bound to
sodium dodecyl sulfate (SDS) micelles or large unilamellar vesicles
(LUVs) composed of 1,2-dioleoyl-sn-glycero-3-phospho-L-serine
(DOPS). In the middle panel, the SDS-bound structure of αS (PDB
entry 1XQ8) and a model of the LUV-bound αS structure, colored to
match the sequence diagram in Figure 1, are shown for comparison to
the FP data.37,39 The right panels are images of Fam-labeled αS
constructs bound to giant unilamellar vesicles (GUVs) composed of
DOPS and Texas Red-1,2-dihexadecanoyl-sn-glycero-3-phosphoetha-
nolamine. Numbers indicate the position of the Fam label on αS
constructs. The scale bar is 10 μm.
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incorporation of αS into fibrils or the resulting supramolecular
structure (see Table 1.
For those label positions ruled to be sufficiently non-
perturbing, we examined the FP measurements of isolated
fibrils. After 48 h, fibrils were pelleted by centrifugation and
resuspended in buffer, and FP was measured, showing only
slight differences between positions, reflecting the expected
high degree of conformational restriction within fibrils.
However, even in these fibrils that are >100 nm in length,
the FP values are still significantly less than 470 mP, the
limiting value for the polarization (anisotropy) of fluorescein.44
This means that even in fibrils, some dynamic range remains
that allows us to interpret local differences in FP that reflect
conformational dynamics in a site-dependent manner. For
example, we can see that the C-terminal tail is more restricted
for αS molecules within fibrils than for SDS-bound αS. This is
interesting in light of previous studies of αS fibrils, particularly
recent solid state NMR studies by Rienstra and co-workers.18
Although they do not observe crosspeaks allowing them to
assign structures to the terminal regions of αS, our data suggest
that these regions are conformationally restricted in fibrils. It
should be noted that our aggregation conditions differ from
theirs, and our measurements are taken on suspensions rather
than packed fibrils for NMR; therefore, this may contribute to
differences in our observations.
We also examined aggregation reactions near t1/2 to see
whether we could observe oligomers or other intermediates
using FP. We pelleted the insoluble material after aggregation
for 6, 9, or 12 h and measured the FP of the supernatant and of
the pellet after resuspension (see Figure S13). We found that
the FP readings of the supernatant remained similar to those of
monomeric αS, suggesting that the remaining soluble species
do not differ considerably from monomeric αS with respect to
fluorophore conformational freedom. In contrast, the FP
readings of the pellet were intermediate between monomer
and fibril levels and grew steadily during aggregation. This may
reflect the presence of smaller, protofibril aggregates at 6, 9, and
12 h, or it may be due to difficulties in completely washing away
the monomer from these very small pellets. Further analysis of
aggregations at early time points using techniques such as
atomic force microscopy (AFM) will be required to determine
the nature of these intermediate FP signals.
We next chose to examine whether we could use this
technique to monitor the disaggregation of αS fibrils. We began
by using harsh conditions known to reliably dissolve fibrils,
boiling in the presence of SDS.45 αS fibrils containing each
labeled construct were agitated for 48 h and separated from the
aggregation reaction mixture by centrifugation. The freshly
resuspended fibrils were then treated with excess SDS, boiled
for 15 min, and allowed to cool to room temperature.
Following the disaggregation procedure, the FP values
uniformly decreased to those corresponding to the SDS-
bound conformation observed previously by direct addition of
SDS to monomeric αS (Figure S16). Sedimentation gel
analyses confirmed that αS fibrils were efficiently dissolved
following treatment with SDS. These studies demonstrate that
we can use FP to reliably monitor the dissolution of αS fibrils
without the addition of any exogenous small molecule probe
such as ThT.
Several small molecules are known to remodel and/or
disaggregate preformed αS fibrils.21,22,26,27,46−51 In some cases,
it has been shown that remodeled αS is less toxic to cultured
neurons. However, the molecular details underlying these
structural changes and how they mitigate fibril toxicity are
poorly understood. Dopaminergic nerve cell death is one of the
pathological hallmarks of PD.1 Thus, several groups have
examined the effect of dopamine and its oxidized derivatives on
the assembly of αS.46,48,50−52 In 2004, Li et al.21 reported that
dopamine treatment led to the disaggregation of preformed αS
fibrils. Surprisingly, the dopamine-mediated disaggregation of
αS fibrils has not been described since this initial report.
In the following years, several aromatic compounds
containing vicinal hydroxyl groups have been identified as
Figure 3. Monitoring forward aggregation and validating labeled
constructs. The top left panel shows the aggregation kinetics of fibrils
made with WT αS or 1% αS−CFam9 monitored by the Congo Red
(CR) absorbance ratio (540 nm/480 nm) as well as changes in FP.
The top right panels are transmission electron microscopy (TEM)
images showing that fibrils made with 1% αS−CFam9 are morpholog-
ically similar to WT αS fibrils. The scale bar is 100 nm. In the bottom
panels, gel analysis demonstrates that αS−CFam9 is incorporated into
fibrils stoichiometrically. Standards (Stnds) of 1% αS−CFam9 loaded at
100, 50, 25, and 12.5 μM. Molecular weight (MW) markers at 11, 17,
22, 25, 32, 46, and 58 kDa. The same battery of experiments was
conducted on αS constructs labeled at Cys24, -42, -62, -87, -114, -123,
or -136. These data are shown in the Supporting Information.
Table 1. Forward Aggregation Studies
αS t1/2
CR (h)a t1/2
FP (h)a fibril FP (mP)b width (nm)c
WT 7.5 ± 0.4 NA NA 9.9 ± 0.9
9 7.0 ± 0.1 11.1 ± 0.5 312 ± 4 9.9 ± 0.7
24 6.9 ± 0.1 12.6 ± 0.4 307 ± 7 9.9 ± 0.7
42 7.6 ± 0.3 27 ± 8 330 ± 7 10.0 ± 0.7
62 10 ± 1 17 ± 1 333 ± 6 9.9 ± 0.7
87 10.9 ± 0.7 15.3 ± 0.9 310 ± 5 10.1 ± 0.7
114 10 ± 2 9.4 ± 0.4 335 ± 3 10.0 ± 0.5
123 8 ± 1 6.7 ± 0.2 345 ± 5 10.0 ± 0.8
136 7.5 ± 0.4 6.9 ± 0.4 330 ± 4 9.8 ± 0.7
aFibril kinetic parameters determined by fits to aggregation curves
shown in Figure S11a−c. bFP values for pelleted, resuspended fibrils
determined as described in the Supporting Information. cFibril width
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efficient amyloid remodeling agents. Among the most well-
studied examples is epigallocatechin gallate (EGCG), a
flavonoid that is found in high concentrations in green tea. In
2010, Bieschke et al.23 demonstrated that EGCG transforms αS
fibrils into smaller oligomeric species that are nontoxic to
mammalian cells. Time-resolved TEM and AFM imaging
revealed that EGCG converts αS fibrils into poorly defined
amorphous aggregates. CD spectroscopy experiments showed a
progressive loss of β-sheet content in the presence of EGCG,
demonstrating that binding of the compound led to a
significant alteration of αS secondary structure. ThT binding
measurements were consistent with a decreasing amyloid
content. However, because EGCG and ThT likely compete for
similar binding sites, the reported remodeling kinetics may be
unreliable and reveal no information about local conformational
changes.
Having shown that we can use FP to monitor αS folding,
aggregation, and disaggregation, we reasoned that we could use
this technique to gain insight into the mechanism by which
small molecules remodel αS fibrils. Here, we chose to examine
the remodeling capacity of dopamine, EGCG, and an additional
flavonoid, nordihydroguiaretic acid (NDGA). Previously,
NDGA has been shown to inhibit αS aggregation and to
disassemble αS oligomers that form in the presence of FeCl3.
27
However, prior to this work, the effect of NDGA treatment on
the structure of αS fibrils has not been described.
Fibrils containing each labeled mutant were treated with
dopamine, EGCG, or NDGA and continuously monitored
using FP (Figure 4A−D). Prolonged incubation with
stoichiometric or excess amounts of dopamine had little effect
on the observed FP values for any of the labeled mutants when
compared to those from control experiments with buffer alone.
These data are consistent with TEM images of WT αS samples,
which do not show significant changes in the morphology of
fibrils from dopamine-treated samples as compared to those
treated with buffer only (Figure 4H−K and Supporting
Information). In contrast, rapid changes in FP for several
labeled constructs were seen upon addition of EGCG or
NDGA. For EGCG, larger changes in FP occurred for labels at
C-terminal residues (114, 123, and 136), consistent with earlier
reports suggesting that EGCG preferentially interacts with the
C-terminus of αS in oligomers.47,49 Remarkably, treatment with
excess NDGA produced a substantial change in FP for labels at
every position except 62. These proteinwide changes may be
indicative of the binding of multiple molecules of NGDA per
αS molecule, resulting in dramatic remodeling of αS fibrils.
Indeed, the fact that we observe quenching of Fam at many
locations upon addition of EGCG or NDGA supports this idea.
Control experiments demonstrating that the observed effects
on FP are not simply the result of fluorescence quenching but
must result from changes in local protein dynamics are detailed
in the Supporting Information. In all cases, the fibrils were
treated with a 10-fold excess of the small molecule relative to
the number of αS monomers in the fibrils. Early experiments
with a more limited number of labeled constructs showed that
no significant changes in FP occurred with substoichiometric
levels of small molecules (see Figure S20).
We have further analyzed the dopamine, EGCG, and NDGA
reactions at the 3 h time point by pelleting the insoluble
material and measuring the FP of the resuspended pellet and
the supernatant (Figure 4F). We performed the resuspensions
with buffer containing the small molecule used in the
Figure 4. Monitoring fibril disaggregation by FP. (A−D) Fibrils made with 1% Fam-labeled αS constructs (at position 9, 24, 42, 62, 87, 114, 123, or
136) were incubated with solutions of buffer, dopamine (Dop), epigallocatechin gallate (EGCG), or nordihydroguiaretic acid (NDGA). FP
measurements are normalized to aid comparison of kinetics. Raw FP values are reported in the Supporting Information. (E) After incubation for 3 h,
the reaction mixtures were pelleted by centrifugation. A portion of the insoluble fraction was boiled in SDS and loaded onto a gel for quantification
relative to buffer-treated fibrils, as described in the Supporting Information. (F and G) FP measurements of the resuspended insoluble and soluble
fractions are shown. FP data for untreated fibrils and for monomer are shown for comparison. (H−K) TEM images of WT αS fibrils, treated with the
same disaggregation protocol, deposited on copper grids, and negatively stained with ammonium molybdate. The scale bar is 200 nm. Larger TEM
images are shown in Figure S31a−d.
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disaggregation reaction to ensure that switching the solvent did
not perturb the reversible binding of small molecules to alter
the conformations of the pelleted αS aggregates. We found that
the insoluble fractions of the dopamine-treated samples and
buffer-treated samples had FP readings that were similar at all
positions except 62. The FP values for the insoluble fractions of
the EGCG- and NDGA-treated samples were slightly higher at
N-terminal and NAC positions, but lower at the far C-terminus.
TEM images of WT αS fibrils treated with the small molecules
show fibrils that are not significantly different in morphology
than those treated with buffer alone (Figure 4H−K, additional
images in Supporting Information). The most obvious
difference is a reduction in the surface coverage of the TEM
grids following treatment with EGCG or NDGA. The TEM
images are consistent with gel-based measurements of the
amount of protein remaining in the insoluble fraction (Figure
4E and Figure S25A,B).
Examination of the FP values for the soluble fractions shows
a clear difference among dopamine, EGCG, and NDGA
treatment (Figure 4G). Dopamine samples have FP values
that are relatively similar to monomer values at each position,
although gel analysis shows that very little protein is solubilized
by dopamine treatment as compared to EGCG or NDGA
treatment. It is notable that the dopamine FP values for
positions 123 and 136 are higher, consistent with reports that
dopamine binds to this region of αS.50 EGCG FP readings are
consistent with the formation of large, amorphous aggregates,
as previously postulated.23,47 NDGA FP values at each position
are also higher than for monomers or micelle-bound αS, except
for a very mobile C-terminus. These data demonstrate that
both EGCG and NDGA are able to solubilize αS from fibrils
and lead to increased degrees of conformational freedom in
many regions of the protein, indicating a significant structural
change.
We have considered two potential mechanisms for the
interpretation of these data. For mechanism 1, it is known that
αS monomers can be shed from fibrils at low levels.15,53 Indeed,
our own size exclusion chromatography (SEC) analysis
demonstrates the shedding of 5−10% monomer under buffer-
only disaggregation control conditions (see Figures S18 and
S19). Therefore, it is possible that EGCG or NDGA binds to
these shed monomers, leading to the formation of the soluble
oligomers observed by FP. This monomer-to-oligomer
transition would drive further fibril-to-monomer transitions
by mass action and would effectively convert fibrils to
oligomers. For mechanism 2, a simpler model for disaggrega-
tion would involve direct binding of EGCG or NDGA to fibrils,
inducing a conformational change that leads directly to the
shedding of oligomers. Of course, hybrid mechanisms are also
possible, but for the preliminary studies presented here, we
considered only these two mechanistic extremes.
Several lines of evidence support mechanism 2, direct
binding of the small molecules to fibrils. First, treating WT
fibrils with EGCG or NDGA in the presence of ThT shows a
rapid decrease in ThT fluorescence, with nearly complete
disappearance after 15 min (Figure S17). However, SDS−
PAGE experiments demonstrate that the amounts of insoluble
αS are still large (60−70%) after a 15 min EGCG or NDGA
treatment (Figure S26). This implies that the decrease in ThT
fluorescence is the result of interactions of EGCG and NDGA
with fibril-bound ThT or competition for binding sites on the
fibrils, rather than actual disaggregation. Second, treatment of
the labeled αS monomer with dopamine, EGCG, or NDGA
does not lead to an observed change in FP over the time frame
of the experiment, showing that the small molecules do not
trigger conformational change or oligomerization that can be
observed by FP when added to monomer (Figure S11). Third,
we have observed fluorophore quenching shortly after addition
of the small molecules to fibrils containing αS−CFamX variants,
which implies contact between the EGCG or NDGA and each
of the Fam labels (Figure S22). Taken together, these results
suggest that EGCG and NDGA directly interact with fibrils at
multiple sites, causing changes in conformational freedom
reported by the fluorescent label.
The observed FP values for the solubilized species imply that
EGCG-solubilized αS aggregates are less conformationally
mobile with respect to the fluorophore sites than NDGA-
solubilized aggregates (possibly involving aggregation of the
small molecules, as well), but additional study will be necessary
to confirm this. Preliminary CD studies of the dopamine-,
EGCG-, and NDGA-treated fibrils show that substantial β-sheet
character is still present in all three cases (see Figure S27). SEC
analysis reveals the presence of oligomers following treatment
with EGCG (see Figures S18 and S19). The observed peak
intensity of the oligomeric species decreases following
sedimentation, indicating limited solubility and/or equilibrium
with sufficiently large species that they cannot be observed by
SEC. Treatment of fibrils with NDGA does not lead to the
observation of an oligomeric αS peak in the SEC chromato-
gram, suggesting that the species formed are sufficiently large
that they are also filtered out upon loading of the SEC column.
It is likely that the solubilized species involve covalent or
noncovalent adducts with oxidized forms of EGCG or NDGA.
Oxidation reactions of dopamine,54 EGCG,55,56 and
NDGA57,58 can lead to complex mixtures of molecules.
Oxidized dopamine metabolites have been reported to form
covalent adducts with αS.59−61 EGCG has been proposed to
form covalent or noncovalent adducts with proteins,62
including amyloid fibrils.63 Our preliminary studies with
tetramethylated NDGA (mNDGA) indicate that oxidation
may indeed be important to disaggregation, as mNDGA, which
cannot form o-quinone oxidation products, does not have a
substantial effect on αS fibrils (see Figure S26). Further
investigations of the solubilized products using biophysical
techniques and treatments with specific oxidation products are
underway and will be reported subsequently.
■ CONCLUSIONS
Here, we have shown that site-specifically labeled αS can be
used in FP experiments to monitor various processes, including
SDS- and LUV-induced folding, fibril formation, disaggregation,
and fibril remodeling induced by exogenous small molecules. In
all cases, we have shown that site-specific Fam labels yield
information about local protein dynamics in a manner that is
compatible with screening in multiwell plate formats. Although
other groups have shown that certain small molecules can
remodel αS fibrils into amorphous, nontoxic species, the
molecular basis for this effect is not well understood and is
likely obscured by competition between the small molecule and
reporter dyes, such as ThT or CR, for protein binding sites.
Our results suggest that EGCG preferentially binds to and
remodels the C-terminus of αS in fibrils, yielding soluble
aggregates, whereas excess dopamine has little effect on the
structure of αS fibrils. NDGA, which has not previously been
explored as a disaggregant, had the most dramatic effect,
mobilizing all regions of αS. Given the evidence of a role for
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oxidation and multiple binding sites in the effects of EGCG and
NDGA on fibrils, further study will be needed to fully
understand the mechanistic details of their actions and the
structures of the resulting solubilized aggregates. Nonetheless,
our studies show that our FP assay can yield information about
the disaggregation process more accurately than information
from typical ThT or CR high-throughput experiments. In the
future, FP assays with labeled constructs validated here can be
used to screen small molecules in efforts to discover novel
compounds with enhanced therapeutic potential for PD.
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